Telix Pharmaceuticals (TLX) Current Assets (2023 - 2025)
Telix Pharmaceuticals (TLX) posted quarterly Current Assets of $330.3 million for Q4 2025, down 45.02% year-over-year from $600.7 million in Q4 2024, and down 45.02% quarter-over-quarter from $600.7 million in Q4 2024.
Telix Pharmaceuticals (TLX) Current Assets (2023 - 2025) Analysis & Trends
Telix Pharmaceuticals (TLX) has reported Current Assets for 3 consecutive years, with $330.3 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Current Assets fell 45.02% year-over-year to $330.3 million; the TTM figure through Dec 2025 stood at $330.3 million (down 45.02% YoY), while the FY2025 annual figure was $330.3 million, down 42.07% from the prior year.
- Current Assets eased to $330.3 million in Q4 2025 per TLX's latest filing, from $600.7 million in the prior quarter.
- Across five years, Current Assets topped out at $600.7 million in Q4 2024 and bottomed at $151.4 million in Q4 2023.
- Historically, Current Assets has averaged $360.8 million across 3 years, with a median of $330.3 million in 2025.
- Annual changes were most pronounced in 2024 — Current Assets soared 296.87% — and 2025, when it plunged 45.02%.
- Telix Pharmaceuticals' Current Assets stood at $151.4 million in 2023, then jumped by 296.87% to $600.7 million in 2024, then slumped by 45.02% to $330.3 million in 2025.
- Business Quant data shows TLX's Current Assets at $330.3 million in Q4 2025, $600.7 million in Q4 2024, and $151.4 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Telix Pharmaceuticals | 4.00 Bn | 3.86 Bn | - | 330.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 330.28 Mn |
| Dec 31, 2024 | 600.70 Mn |
| Dec 31, 2023 | 151.36 Mn |